Back to Press Releases

Axcella Announces Oral Presentation at 2020 International Conference on Frailty and Sarcopenia Research

March 5, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that it will give an oral presentation at the 2020 International Conference on Frailty and Sarcopenia (ICFSR) in Toulouse, France on March 12, 2020.

During the presentation, Axcella Principal Scientist William Comb, Ph.D. will describe how data science and physiological primary cell models are being utilized to interrogate targeted biologies and design EMM compositions with the potential to influence multiple pathways simultaneously, using Axcella’s AXA2678 muscle product candidate as a model.

Abstract to be presented:

Title: Development of an in vitro platform to predict and screen combinations of endogenous metabolic modulators capable of influencing muscle physiology
Location: Hôtel-Dieu Saint-Jacques, Ballroom 1
Time: March 12, 2020 - 2:45 pm CET

About Endogenous Metabolic Modulators (EMMs)

EMMs are a broad family of molecules, including amino acids, that regulate human metabolism. Axcella is developing a range of novel product candidates that are comprised of multiple EMMs and their derivatives engineered in distinct combinations and ratios to simultaneously impact multiple metabolic pathways to modify the root causes of various complex diseases and improve health.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor such portions of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the prevention of recurrent overt hepatic encephalopathy (OHE). Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the development potential of Axcella’s platform and product candidates, including the ability of its primary cell models to interrogate biologies and design EMM compositions, including AXA2678, with the potential to influence multiple pathways simultaneously. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward looking statements contained in this press release, including, without limitation, those related to the breadth and potential uses of the company’s pipeline of product candidates, the efficiency of the company’s discovery and development approach, the clinical development and safety profile of the company’s product candidates and their health or therapeutic potential, whether and when, if at all, the company’s product candidates will receive approval from the U.S. Food and Drug Administration, or other comparable regulatory authorities, and for which, if any, indications, competition from other biotechnology companies, the company’s liquidity, its ability to successfully develop product candidates through current and future milestones on the anticipated timeline, if at all, past results from non-IND clinical studies not being representative of future results, and other risks identified in the company’s SEC filings, including Axcella’s Quarterly Report on Form 10-Q and subsequent filings with the SEC. The company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Axcella disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The company explicitly disclaims any obligation to update any forward-looking statements.

Company/Investor Contact
Jason Fredette
jfredette@axcellahealth.com
857.320.2236

Media Contact
Azeem Zeekrya
HDMZ
azeem.zeekrya@hdmz.com
312-506-5244

Source: Axcella